Patents Assigned to Gilead Sciences, Inc.
  • Patent number: 11224600
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 18, 2022
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11225473
    Abstract: The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Morin Mae Frick, Elizabeth M. Horstman, Joshua A. Kaplan, Jeffrey E. Kropf, William J. Watkins
  • Patent number: 11213523
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: January 4, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Mingzhe Ji, Haolun Jin, Hyung-Jung Pyun, Teresa Alejandra Trejo Martin
  • Patent number: 11203591
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: December 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Patent number: 11202780
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • Patent number: 11186579
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 30, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Kristyna M. Elbel, Rao V. Kalla, Xiaofen Li, Thao Perry
  • Patent number: 11179397
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 23, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory Chin, Michael O' Neil Hanrahan Clarke, Xiaochun Han, Tim Hansen, Yunfeng Eric Hu, Dmitry Koltun, Ryan McFadden, Michael R. Mish, Eric Q. Parkhill, David Sperandio, Lianhong Xu, Hai Yang
  • Patent number: 11179383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 23, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11174256
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11168130
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 9, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Mini Balakrishnan, Brian A. Carr, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • Publication number: 20210323922
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: November 13, 2020
    Publication date: October 21, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Patent number: 11124487
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 21, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 11124582
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: September 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • Patent number: 11117886
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: September 14, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Amanda Lynn Vandehey, Gediminas Brizgys, Vinh Xuan Ngo, Brian Michael O'Keefe, Trevor James Rainey, Bing Shi, Winston C. Tse, Anna Michelle Wagner, Xianghong Wang, Scott Alan Wolckenhauer, Jennifer R. Zhang
  • Patent number: 11116760
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: September 14, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11116774
    Abstract: Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula II: and pharmaceutically acceptable salts thereof, useful in treating HIV infections.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 14, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Romas Geleziunas, Joseph E. Hesselgesser
  • Patent number: 11110091
    Abstract: Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: September 7, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Randall L. Halcomb, Paul Hrvatin, Hon Chung Hui, Ryan McFadden, Paul A. Roethle, Hong Yang
  • Patent number: 11098027
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 24, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Patent number: 11084832
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: August 10, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Patent number: RE48711
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 31, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte